Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...
Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma. The Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results